Hepatocyte mARC1 promotes fatty liver disease

Lara C. Lewis; Lingyan Chen; L. Shahul Hameed; Robert R. Kitchen; Cyrielle Maroteau; Shilpa R. Nagarajan; Jenny Norlin; Charlotte E. Daly; Iwona Szczerbinska; Sara Toftegaard Hjuler; Rahul Patel; Eilidh Livingstone; Tom N. Durrant; Elisabeth Wondimu; Soumik BasuRay; Anandhakumar Chandran; Wan-Hung Lee; Sile Hu; Barak Gilboa; Megan E. Grandi; Enrique M. Toledo; Abdullah H.A. Erikat; Leanne Hodson; William G. Haynes; Natalie W. Pursell; Ken Coppieters; Jan Fleckner; Joanna M. M. Howson; Birgitte Andersen; Maxwell A. Ruby

doi:10.1016/j.jhepr.2023.100693

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

We report that genetically predicted increases in MTARC1 mRNA associate with poor liver health. Furthermore, knockdown of mARC1 reduces hepatic steatosis in primary human hepatocytes and a murine NASH model. Together, these findings further underscore the therapeutic potential of targeting hepatocyte MTARC1 for NAFLD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lewis et al. (2023) studied this question.

synapsesocial.com/papers/69d7b9e96a6ff5a83cbed848 https://doi.org/10.1016/j.jhepr.2023.100693

View Full Paper

Ask AI

Bookmark

Share

Hepatocyte mARC1 promotes fatty liver disease

Ask about this paper

Abstract

Discussion

Cite This Study

Hepatocyte mARC1 promotes fatty liver disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading